Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

A complex role of herpes viruses in the disease process of multiple sclerosis.
Binding of recombinant T cell receptor ligands (RTL) to antigen presenting cells prevents upregulation of CD11b and inhibits T cell activation and transfer of experimental autoimmune encephalomyelitis.
BG00012 and Disability Progression in Secondary Progressive Multiple Sclerosis (SPMS) (INSPIRE)
The potential teratogenic effects of interferon beta-1a (IFNβ-1a) and interferon beta-1b (IFNβ-1b) on in vitro embryonic development.
Multigate Quality Doppler Profiles and Morphological/Hemodynamic Alterations in Multiple Sclerosis Patients.
A controlled trial of mitoxantrone in multiple sclerosis: serial MRI evaluation at one year.
Toll-like receptor 2 and poly(ADP-ribose) polymerase 1 promote central nervous system neuroinflammation in progressive EAE.
Effects of prophylactic and therapeutic teriflunomide in transcranial magnetic stimulation-induced motor-evoked potentials in the Dark Agouti rat model of experimental autoimmune encephalomyelitis.
Biogen Idec receives negative opinion from the CHMP on Fampyra
Colestipol May Quickly Eliminate Teriflunomide
Receptos Completes Enrollment of RADIANCE Phase 3 Trial of Ozanimod in Relapsing Multiple Sclerosis
Polymorphisms in the receptor tyrosine kinase MERTK gene are associated with multiple sclerosis susceptibility.
Environmental risk factors for multiple sclerosis. Part I: the role of infection.
Rituximab in Steroid-Dependent or Frequently Relapsing Idiopathic Nephrotic Syndrome.
New approaches in the management of multiple sclerosis.
The short-term effect of an immunosuppressive treatment on CSF myelin basic protein in chronic progressive multiple sclerosis.
Phase II Cladribine Add-on to Interferon-beta (IFN-b) Therapy in MS Subjecs With Active Disease (ONWARD)
Fingolimod is a potential novel therapy for multiple sclerosis.
Daclizumab (anti-CD25) in multiple sclerosis.
Rare variants in the CYP27B1 gene are associated with multiple sclerosis.
Evidence for the efficacy of interferon beta-1b in delaying the onset of clinically definite multiple sclerosis in individuals with clinically isolated syndrome.
Peripheral and Central Nervous System Drugs Advisory Committee Meeting: Alemtuzumab (BLA 103948\5139) Background Package
The NF-κB regulator MALT1 determines the encephalitogenic potential of Th17 cells.
Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial.
Integrated genomic and prospective clinical studies show the importance of modular pleiotropy for disease susceptibility, diagnosis and treatment.

Pages